petosemtamab

News

Genmab agrees $8bn takeover of cancer biotech Merus

Genmab continues its shift from out-licensing drugs to developing its own drugs with an $8bn deal to buy Merus and its head and neck cancer therapy.

News

ASCO 25: Merus bispecific scores again in HNSCC

For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye.

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petosemtamab in he

Genmab agrees $8bn takeover of cancer biotech Merus

ASCO 25: Merus bispecific scores again in HNSCC

ASCO: Merus bispecific garners attention after abstract drop

Tenax trounced by phase 3 heart failure readout

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks